Search Clinical Trials in the EU

Duration

>20 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

41-60 of 140 trials

Lupus Treatment: BIIB059 Study

We are testing a new medication, BIIB059, for people with active subacute or chronic cutaneous lupus who haven't responded to standard treatments. The study aims to see if it can reduce skin disease activity and improve overall safety.

Skin Lupus1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Investigational Medicines Cost Reimbursement Partially RemoteDermatologyRheumatology

Ulcerative Colitis: Lutikizumab Treatment Study

We are assessing the safety and effectiveness of lutikizumab in adults with active ulcerative colitis. This study compares it to an existing treatment to see if it offers better results.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Lung Cancer Treatment: Livmoniplimab and Budigalimab

We are studying a new combination of drugs for adults with untreated metastatic non-squamous non-small cell lung cancer. The goal is to see if this combination works better than a standard treatment with pembrolizumab and chemotherapy.

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Severe Community-Acquired Pneumonia: AON-D21 Treatment Study

We are testing a new drug, AON-D21, as an additional treatment for patients with severe community-acquired pneumonia in intensive care. The study aims to assess its safety and effectiveness compared to a placebo.

Severe Community-Acquired Pneumonia≤3 monthsEfficacy phase (II)>20 visits Investigational Medicines Cost ReimbursementInternal MedicinePulmonology

Myotonic Dystrophy Type 1: VX-670 Study

We are testing the safety and tolerability of a new drug, VX-670, in adults with myotonic dystrophy type 1. This study aims to understand how the drug works in the body and its potential benefits.

Myotonic DystrophySafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurology

Weight Management in Schizophrenia: Semaglutide Study

We are investigating whether semaglutide can help patients with schizophrenia and obesity improve their weight and metabolic health. This study compares semaglutide to a placebo to see its effects on various health measures.

Metabolic Control in Antipsychotic-Using Patients6-12 monthsConfirmation phase (III)>20 visits Investigational MedicinesEndocrinologyPsychiatry

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemotePediatricsRheumatology

Neonatal OTC Deficiency: ECUR-506 Treatment Study

We are investigating a new treatment called ECUR-506 for boys under 9 months with neonatal onset OTC deficiency. The study will help us understand its safety and how well it works.

Ornithine Transcarbamylase Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteInternal MedicinePediatrics

Atopic Dermatitis: Long-Term Study of Amlitelimab

We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.

Atopic Dermatitis>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)>20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurologyOrthopedics and Traumatology

Immunoglobulin A Nephropathy: Sibeprenlimab Study

We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.

IgA Nephropathy>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteNephrology

Hemophilia A: Long-Term Follow-Up of BMN 270

We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.

Hemophilia A>2 yearsMonitoring phase (IV)>20 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematology

iTTP Treatment: TAK-755 Study

We are testing a new treatment called TAK-755 for patients with immune-mediated thrombotic thrombocytopenic purpura. The study aims to see if it is safe and effective in reducing symptoms and preventing future episodes.

Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)≤3 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematology

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Ulcerative Colitis: GS-1427 Study

We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Metastatic Pancreatic Adenocarcinoma: TTX-030 and Chemotherapy

We are studying if adding TTX-030 and possibly budigalimab to standard chemotherapy helps patients with untreated metastatic pancreatic cancer. This trial aims to evaluate the effectiveness and safety of these combinations.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)>20 visits No Placebo Investigational Medicines Partially RemoteGastroenterologyOncology

Seasonal Allergic Rhinitis: PQ Grass Treatment for Kids

We are studying a new treatment for children and teens with seasonal allergic rhinitis caused by grass pollen. The goal is to see if it helps reduce symptoms and is safe for long-term use.

Allergic Rhinitis and Conjunctivitis>2 yearsConfirmation phase (III)>20 visits Standard Medicines Cost Reimbursement Partially RemoteAllergologyPediatrics

Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study

We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.

Familial Chylomicronemia Syndrome>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteEndocrinologyHematology

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterology

Search Clinical Trials in the European Union